[go: up one dir, main page]

CY1110640T1 - Μεθοδος συνθεσης συζευγματων πολυπεπτιδιου ινσουλινης -ολιγομερους και συζευγματων πολυπεπτιδιου προϊνσουλινης- ολιγομερους και μεθοδοι συνθεσης αυτων - Google Patents

Μεθοδος συνθεσης συζευγματων πολυπεπτιδιου ινσουλινης -ολιγομερους και συζευγματων πολυπεπτιδιου προϊνσουλινης- ολιγομερους και μεθοδοι συνθεσης αυτων

Info

Publication number
CY1110640T1
CY1110640T1 CY20101100072T CY101100072T CY1110640T1 CY 1110640 T1 CY1110640 T1 CY 1110640T1 CY 20101100072 T CY20101100072 T CY 20101100072T CY 101100072 T CY101100072 T CY 101100072T CY 1110640 T1 CY1110640 T1 CY 1110640T1
Authority
CY
Cyprus
Prior art keywords
polypeptide
conjugates
proinsulin
oligomer
insulin
Prior art date
Application number
CY20101100072T
Other languages
English (en)
Inventor
Richard Soltero
Balasingham Radhakrishnan
Nnochiri N Ekwuribe
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/036,744 external-priority patent/US6913903B2/en
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of CY1110640T1 publication Critical patent/CY1110640T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Περιγράφονται μέθοδοι για σύνθεση πολυπεπτιδίων προϊνσουλίνης που περιλαμβάνουν επαφή ενός πολυπεπτιδίου προϊνσουλίνης το οποίον περιλαμβάνει ένα πολυπεπτίδιο ινσουλίνης συζευγμένο με ένα ή περισσότερα πεπτίδια μέσω πεπτιδικού (-ών) δεσμού(-ών) ικανό να διασπαρθεί ώστε να δώσει το πολυπεπτίδιο ινσουλίνης με ένα ολιγομερές υπό συνθήκες επαρκείς για σύζευξη του ολιγομερούς με το τμήμα πολυπεπτιδίου ινσουλίνης του πολυπεπτιδίου προϊνσουλίνης και να παρασχεθεί ένα σύζευγμα πολυπεπτιδίου προϊνσουλίνης -ολιγομερούς, και διάσπαση ενός ή περισσοτέρων πεπτιδίων από το σύζευγμα πολυπεπτιδίου προϊνσουλίνης -ολιγομερούς ώστε να παρασχεθεί το σύζευγμα πολυπεπτιδίου ινσουλίνης-ολιγομερούς. Περιγράφονται επίσης μέθοδοι για σύνθεση συζευγμάτων πολυπεπτιδίου προϊνσουλίνης -ολιγομερούς όπως και συζεύγματα πολυπεπτιδίου προϊνσουλίνης-ολιγομερούς. Περιγράφονται επίσης μέθοδοι σύνθεσης συζευγμάτων C-πεπτιδίου του πολυπεπτιδίου-ολιγομερούς.
CY20101100072T 2001-09-07 2010-01-22 Μεθοδος συνθεσης συζευγματων πολυπεπτιδιου ινσουλινης -ολιγομερους και συζευγματων πολυπεπτιδιου προϊνσουλινης- ολιγομερους και μεθοδοι συνθεσης αυτων CY1110640T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31819701P 2001-09-07 2001-09-07
US10/036,744 US6913903B2 (en) 2001-09-07 2001-12-21 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US34946202P 2002-01-18 2002-01-18
EP02766246A EP1430082B1 (en) 2001-09-07 2002-09-06 Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same

Publications (1)

Publication Number Publication Date
CY1110640T1 true CY1110640T1 (el) 2015-04-29

Family

ID=27365090

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100072T CY1110640T1 (el) 2001-09-07 2010-01-22 Μεθοδος συνθεσης συζευγματων πολυπεπτιδιου ινσουλινης -ολιγομερους και συζευγματων πολυπεπτιδιου προϊνσουλινης- ολιγομερους και μεθοδοι συνθεσης αυτων

Country Status (16)

Country Link
EP (1) EP1430082B1 (el)
JP (1) JP4318546B2 (el)
AR (1) AR036449A1 (el)
AT (1) ATE446971T1 (el)
AU (1) AU2002329989A1 (el)
CY (1) CY1110640T1 (el)
DE (1) DE60234198D1 (el)
DK (1) DK1430082T3 (el)
ES (1) ES2333781T3 (el)
MY (1) MY127575A (el)
PE (1) PE20030536A1 (el)
PT (1) PT1430082E (el)
SA (1) SA02230453B1 (el)
SI (1) SI1430082T1 (el)
UY (1) UY27439A1 (el)
WO (1) WO2003022996A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
JP5047978B2 (ja) * 2005-10-13 2012-10-10 バイオコン・リミテッド インスリン複合体の調製のための方法
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
PL2074141T3 (pl) 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
NZ603399A (en) 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
CN105636979B (zh) 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
US20180169190A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
CN112312923A (zh) * 2018-06-18 2021-02-02 拜康有限公司 控制对象的餐后葡萄糖水平的方法和用途
CN113087623A (zh) * 2021-04-13 2021-07-09 苏州昊帆生物股份有限公司 一种8-溴辛酸乙酯的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4431740A (en) * 1979-09-12 1984-02-14 The Regents Of The University Of California DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
EP0792290B1 (en) 1993-09-17 2001-08-29 Novo Nordisk A/S Acylated insulin
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same

Also Published As

Publication number Publication date
JP4318546B2 (ja) 2009-08-26
EP1430082A2 (en) 2004-06-23
SI1430082T1 (sl) 2010-02-26
WO2003022996A3 (en) 2003-12-31
DK1430082T3 (da) 2010-01-18
PT1430082E (pt) 2010-01-15
JP2005502353A (ja) 2005-01-27
WO2003022996A2 (en) 2003-03-20
DE60234198D1 (de) 2009-12-10
PE20030536A1 (es) 2003-07-03
EP1430082A4 (en) 2004-11-24
MY127575A (en) 2006-12-29
AR036449A1 (es) 2004-09-08
AU2002329989A1 (en) 2003-03-24
SA02230453B1 (ar) 2008-02-05
EP1430082B1 (en) 2009-10-28
ES2333781T3 (es) 2010-03-01
UY27439A1 (es) 2003-04-30
ATE446971T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
CY1110640T1 (el) Μεθοδος συνθεσης συζευγματων πολυπεπτιδιου ινσουλινης -ολιγομερους και συζευγματων πολυπεπτιδιου προϊνσουλινης- ολιγομερους και μεθοδοι συνθεσης αυτων
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1108507T1 (el) Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc
ES2149149T1 (es) Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion.
CY1109377T1 (el) Gpl-1 πρωτεϊνες συντηξης
ATE490969T1 (de) Modifizierte transferrin-fusionsproteine
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
WO2004083234A3 (en) Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
BR0314092A (pt) proteìnas de fusão de transferrina modificadas
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
EP1315513A4 (en) CHEMICAL LIGATION "PSEUDO" -NATIVE
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
BR0314093A (pt) Proteìnas de fusão de transferrina modificada-anticorpo
CY1107881T1 (el) Τροποποιημενα πεπτιδια ως θεραπευτικοι παραγοντες
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
BRPI0406574A (pt) Conjugados de anticorpo - antraciclina
WO2003031464A3 (en) Remodeling and glycoconjugation of peptides
IS5887A (is) Interferón-beta bræðsluprótín og notkun þeirra
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
ATE444969T1 (de) Dimerisiertes peptid
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
BRPI0413426A (pt) antagonistas de receptor novo